Marras LC, Geerts WH, Perry JR (2000) The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 89(3):640–646. https://doi.org/10.1002/1097-0142(20000801)89:3%3c640::AID-CNCR20%3e3.0.CO;2-E

Article  CAS  PubMed  Google Scholar 

Donnellan E, Khorana AA (2017) Cancer and venous thromboembolic disease: a review. Oncologist 22(2):199–207. https://doi.org/10.1634/theoncologist.2016-0214

Article  PubMed  PubMed Central  Google Scholar 

Vedovati MC, Giustozzi M, Verdecchia P et al (2018) Patients with cancer and atrial fibrillation treated with doacs: a prospective cohort study. Int J Cardiol 269:152–157. https://doi.org/10.1016/j.ijcard.2018.07.138

Article  PubMed  Google Scholar 

Young AM, Marshall A, Thirlwall J et al (2018) Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017–2023. https://doi.org/10.1200/JCO.2018.78.8034

Article  CAS  PubMed  Google Scholar 

Agnelli G, Becattini C, Meyer G et al (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382(17):1599–1607. https://doi.org/10.1056/NEJMoa1915103

Article  CAS  PubMed  Google Scholar 

Raskob GE, Van Es N, Verhamme P et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615–624. https://doi.org/10.1056/NEJMoa1711948

Article  CAS  PubMed  Google Scholar 

Key NS, Khorana AA, Kuderer NM et al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38(5):496–520. https://doi.org/10.1200/JCO.19.01461

Article  PubMed  Google Scholar 

Stevens SM, Woller SC, Kreuziger LB et al (2021) Antithrombotic therapy for VTE disease. Chest 160(6):e545–e608. https://doi.org/10.1016/j.chest.2021.07.055

Article  CAS  PubMed  Google Scholar 

Streiff MB, Holmstrom B, Angelini D et al (2021) Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN 19(10):1181–1201. https://doi.org/10.6004/jnccn.2021.0047

Article  PubMed  Google Scholar 

Schrag D, Uno H, Rosovsky R et al (2023) Direct oral anticoagulants vs low-molecular-weight heparin and recurrent vte in patients with cancer: a randomized clinical trial. JAMA. https://doi.org/10.1001/jama.2023.7843

Article  PubMed  PubMed Central  Google Scholar 

Farge D, Frere C, Connors JM et al (2022) 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 23(7):e334–e347. https://doi.org/10.1016/S1470-2045(22)00160-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fanola CL, Ruff CT, Murphy SA et al (2018) Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc 7(16):e008987. https://doi.org/10.1161/JAHA.118.008987

Article  CAS  PubMed  PubMed Central  Google Scholar 

Melloni C, Dunning A, Granger CB et al (2017) Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial. Am J Med 130(12):1440-1448.e1. https://doi.org/10.1016/j.amjmed.2017.06.026

Article  CAS  PubMed  Google Scholar 

Xiang E, Ahuja T, Raco V, Cirrone F, Green D, Papadopoulos J (2018) Anticoagulation prescribing patterns in patients with cancer. J Thromb Thrombolysis 45(1):89–98. https://doi.org/10.1007/s11239-017-1558-1

Article  CAS  PubMed  Google Scholar 

Carney BJ, Uhlmann EJ, Puligandla M et al (2019) Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. J Thromb Haemost 17(1):72–76. https://doi.org/10.1111/jth.14336

Article  CAS  PubMed  Google Scholar 

Leader A, Hamulyák EN, Carney BJ et al (2020) Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. Blood Adv 4(24):6291–6297. https://doi.org/10.1182/bloodadvances.2020003238

Article  CAS  PubMed  PubMed Central  Google Scholar 

Swartz AW, Drappatz J (2021) Safety of direct oral anticoagulants in central nervous system malignancies. Oncologist 26(5):427–432. https://doi.org/10.1002/onco.13698

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee A, Oley F, Lo M et al (2021) Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors. Thromb Res 208:148–155. https://doi.org/10.1016/j.thromres.2021.10.023

Article  CAS  PubMed  Google Scholar 

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 3(1):1–150

Google Scholar 

Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest 137(2):263–272. https://doi.org/10.1378/chest.09-1584

Article  PubMed  Google Scholar 

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381. https://doi.org/10.1016/j.jbi.2008.08.010

Article  PubMed  Google Scholar 

Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694. https://doi.org/10.1111/j.1538-7836.2005.01204.x

Article  CAS  PubMed  Google Scholar 

Kearon C, Akl EA, Ornelas J et al (2016) Antithrombotic therapy for VTE disease. Chest 149(2):315–352. https://doi.org/10.1016/j.chest.2015.11.026

Article  PubMed  Google Scholar 

January CT, Wann LS, Calkins H et al (2019) AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. https://doi.org/10.1161/CIR.0000000000000665

Article  PubMed  Google Scholar 

January CT, Wann LS, Alpert JS et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol 64(21):e1–e76. https://doi.org/10.1016/j.jacc.2014.03.022

Article  PubMed  Google Scholar 

Carney BJ, Uhlmann EJ, Puligandla M et al (2020) Anticoagulation after intracranial hemorrhage in brain tumors: risk of recurrent hemorrhage and venous thromboembolism. Res Pract Thromb Haemost 4(5):860–865. https://doi.org/10.1002/rth2.12377

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giustozzi M, Proietti G, Becattini C, Roila F, Agnelli G, Mandalà M (2022) ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis. Blood Adv 6(16):4873–4883. https://doi.org/10.1182/bloodadvances.2022008086

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang J, He Z, Li M, Hong T, Ouyang T (2023) Risk of intracranial hemorrhage with direct oral anticoagulation versus low molecular weight heparin in the treatment of brain tumor-associated venous thromboembolism: a meta-analysis. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc 32(8):107243. https://doi.org/10.1016/j.jstrokecerebrovasdis.2023.107243

Article  Google Scholar 

Santiago RB, Shah N, Ali A, Ranjan S. Safety of Direct Oral Anticoagulants as Compared to Low Molecular Weight Heparin in Treating Venous Thromboembolism in Patients with Primary Brain Tumors and Brain Metastases – A Review of Literature and Meta-analysis (S17.005). In: Monday, April 24. Lippincott Williams & Wilkins. 2023 doi:https://doi.org/10.1212/WNL.0000000000203961

Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902–4907. https://doi.org/10.1182/blood-2007-10-116327

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cohen A, Noxon V, Dhamane A et al (2023) Effectiveness and safety of anticoagulants among venous thromboembolism cancer patients with and without brain cancer. Thromb Res 226:117–126. https://doi.org/10.1016/j.thromres.2023.04.009

Article  CAS  PubMed  Google Scholar 

By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023. doi:https://doi.org/10.1111/jgs.18372

Setiawan B, Permatadewi CO, de Samakto B et al (2020) Von willebrand factor:antigen and ADAMTS-13 level, but not soluble P-selectin, are risk factors for the first asymptomatic deep vein thrombosis in cancer patients undergoing chemotherapy. Thromb J 18(1):33. https://doi.org/10.1186/s12959-020-00247-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Obermeier HL, Riedl J, Ay C et al (2019) The role of ADAMTS-13 and von willebrand factor in cancer patients: results from the vienna cancer and thrombosis study. Res Pract Thromb Haemost 3(3):503–514. https://doi.org/10.1002/rth2.12197

Article  CAS  PubMed  PubMed Central